CIK 0000310158 · Large accelerated filer
Merck & Co., Inc.
Sign in to watch- Ticker
- MRK
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NJ
- Entity type
- operating
- EIN
- 221918501
- Phone
- 908-740-4000
- Business address
- 126 EAST LINCOLN AVENUE, P.O. BOX 2000, RAHWAY, NJ, 07065
- Former names
- Merck & Co. Inc., SCHERING PLOUGH CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-06 | Oosthuizen Johannes Jacobus President, U.S. Market | Sale | −15,000 | $121.87 | $1.8M | 21,197.39 |
| 2026-02-06 | DeLuca Richard R. EVP&Pres, Merck Animal Heallth | Sale | −37,685 | $120.92 | $4.6M | 160,173.83 |
| 2026-02-05 | Guindo Chirfi Chief Marketing Officer | Sale | −20,000 | $121.88 | $2.4M | 80,615.13 |
| 2026-02-04 | Smart Dalton E. III SVP Fin. - Global Controller | Option exercise | +4,000 | $62.07 | $248K | 14,604.82 |
| 2026-02-04 | Smart Dalton E. III SVP Fin. - Global Controller | Sale | −4,000 | $119.68 | $479K | 10,604.82 |
| 2026-02-04 | Smart Dalton E. III SVP Fin. - Global Controller | Sale | −2,400 | $119.68 | $287K | 8,204.82 |
| 2026-02-04 | Smart Dalton E. III SVP Fin. - Global Controller | Option exercise · Stock Option (Right to Buy) | −4,000 | 8,130 | ||
| 2026-02-04 | Litchfield Caroline EVP & CFO | Option exercise | +41,997 | $53.06 | $2.2M | 132,189.19 |
| 2026-02-04 | Litchfield Caroline EVP & CFO | Sale | −41,997 | $119.61 | $5.0M | 90,192.19 |
| 2026-02-04 | Litchfield Caroline EVP & CFO | Option exercise · Stock Option (Right to Buy) | −41,997 | 0 | ||
| 2026-02-04 | Li Dean Y Executive VP & President, MRL | Option exercise | +15,087 | $56.04 | $845K | 117,357.05 |
| 2026-02-04 | Li Dean Y Executive VP & President, MRL | Sale | −15,087 | $118.77 | $1.8M | 102,270.05 |
| 2026-02-04 | Li Dean Y Executive VP & President, MRL | Option exercise · Stock Option (Right to Buy) | −15,087 | 0 | ||
| 2026-02-04 | Davis Robert M Chairman, CEO & President | Sale | −14,972 | $117.38 | $1.8M | 476,063.76 |
| 2026-02-04 | Davis Robert M Chairman, CEO & President | Sale | −32,462 | $118.35 | $3.8M | 443,601.76 |
| 2026-01-26 | Zachary Jennifer EVP, General Counsel | Grant or award | +11,583 | $107.40 | $1.2M | 68,915.67 |
| 2026-01-26 | Williams David Michael EVP,Chief Info&Digital Officer | Grant or award | +6,112 | $107.40 | $656K | 30,837.74 |
| 2026-01-26 | Smart Dalton E. III SVP Fin. - Global Controller | Grant or award | +1,066 | $107.40 | $114K | 10,604.82 |
| 2026-01-26 | Romanelli Joseph President, Human Health Int?l | Grant or award | +5,703 | $107.40 | $613K | 28,739.34 |
| 2026-01-26 | Oosthuizen Johannes Jacobus President, U.S. Market | Grant or award | +5,026 | $107.40 | $540K | 36,197.39 |
Page 8 of 19 · 376 trades